Gilead

US will share vaccines and raw materials with other countries

Pexels free to use license. Credit: Alok Uniyal URL: https://www.pexels.com/photo/horizontally-striped-flag-3476860/

This is an excerpt from the April 27, 2021 edition of Medically Necessary, a health care supply chain newsletter. Subscribe here.

The plan: The U.S. plans to release 60 million doses of AstraZeneca’s COVID-19 vaccine, which hasn’t been approved in the U.S., to other countries.

  • A White House spokesperson didn’t specify which countries would receive the vaccine.

In addition, the U.S. will share raw materials for vaccine manufacturing, therapeutics, rapid test kits, ventilators and personal...

https://www.freightwaves.com/news/us-will-share-vaccines-and-raw-materials-with-other-countries

Gilead Signs Billion-dollar Drug Deal for Hepatitis

Gilead has agreed to acquire the German drugmaker Myr Pharmaceuticals and its marketed therapy for chronic hepatitis D, also known as delta hepatitis, reports Fierce Biotech.

The total deal is worth a little over $1 billion.

Deal making spree

Gilead has been on a deal-making tear this year. Looking to strengthen its foundation in cancer research, the California-based biotech has dropped north of $27 billion on a series of research pacts, equity investments and all out acquisitions.

Those deals mark...

https://mfame.guru/gilead-signs-billion-dollar-drug-deal-for-hepatitis/

Scientists Question FDA Remdesivir Approval

  • Scientists have questioned FDA’s emergency authorization of GiLead’s Remdesivir overlooking critical data and evidence.
  • Many have questioned how the company has undermined WHO’s Solidarity trial.
  • The absence of viral load data in FDA’s approval evidence is a critical concern.
  • Scientists say an outside expert panel debate was necessary before the approval
  • Many are comparing this to the authorization of hydroxychloroquine use.

Within a month of publishing clinical trials data showing the effect...

https://mfame.guru/scientists-question-fda-remdesivir-approval/

The Dubious Case of Remdesivir, The First FDA Approved COVID Drug

  • Within weeks of Remdesivir trial data publishing, GiLead signed a EU manufacturing deal and got the drug approved by FDA.
  • The dubious circumstances of the first FDA approved covid drug shows how the company exploited and gained advantage.
  • Breaches and badmouthing of WHO’s solidarity trial is a noted problem
  • Added to this the lack of inclusion of critical study evidences and the absence of any outer panel expert debate for approval makes the matter dubious.

October was a good month for Gilead...

https://mfame.guru/the-dubious-case-of-remdesivir-the-first-fda-approved-covid-drug/

Low Cost Remdesivir Manufacturing License, $64 for 100mg

According to a Reuters report, Mylan NV (MYL.O) said on Monday that they are launching a generic version of Gilead Sciences Inc’s (GILD.O) COVID-19 antiviral remdesivir in India at 4,800 rupees ($64.31), about 80% below the price tag on the drug for wealthy nations.

Why this move?

California-based Gilead has signed licensing deals with several generic drugmakers in an effort to make remdesivir available in 127 developing countries.

Last month, two Indian drugmakers, Cipla Ltd (CIPL.NS) and...

https://mfame.guru/low-cost-remdesivir-manufacturing-license-64-for-100mg/

US Takes World’s Remdesivir Stock , Nearing 100,000 Cases A Day

In a major development, the US has secured the world stock of the covid19 drug remdesivir as infections rage over the country, reports the Guardian.

The report also adds how no country can buy remdesivir now as there is no stock available. The drug will help recover the US to tackle Covid-19, for next three months at least

Experts Alarmed By this Move

The US has bought up virtually all the stocks for the next three months of one of the two drugs proven to work against Covid-19, leaving none for...

https://mfame.guru/us-takes-worlds-remdesivir-stock-nearing-100000-cases-a-day/

First Approved COVID-19 Therapy in EU

  • EU drug regulator endorses Gilead’s remdesivir as COVID-19 treatment.
  • US research group suggests Remdesivir can be priced at up to $5,080 per course, while Indian generic drug-makers will sell the treatment for 5,000 rupees to 6,000 rupees.($66.13-$79.35).
  • The drug hinders certain viruses, including coronavirus, from multiplying and overwhelming the immune system.

Doctors in Europe will soon be able to treat COVID-19 patients with Gilead’s antiviral drug, remdesivir, after the healthcare...

https://mfame.guru/first-approved-covid-19-therapy-in-eu/

Remdesivir Could Become the First Effective Treatment for the Covid-19 

  • Fauci says Remdesivir helps patients to recover much faster. 
  • Gilead suggests that Remdesivir could become the first effective treatment for the Covid-19. 
  • Gilead shares jumped as much as 8.1% after the company’s statement. 
  • The FDA is in talks with Gilead to make the medicine available quickly.
  • Gilead’s study and the NIAID trial could signal a profound shift in the race to get the novel coronavirus under control. 

Michelle Fay Cortez , Naomi Kresge , and Justin Sink write for Bloomberg that...

http://mfame.guru/remdesivir-could-become-the-first-effective-treatment-for-the-covid-19/

Gilead Allege ‘Inappropriate Characterizations’ of Its COVID19 Drug Trial Data!

According to a Reuters report, a closely-watched Gilead Sciences Inc (GILD.O) experimental antiviral drug failed to help patients with severe COVID-19 in a clinical trial conducted in China, but the drugmaker said the findings were inconclusive because the study was terminated early.

Gilead shares closed down 4.3% after the data was inadvertently released and first reported by the Financial Times.

What is it?
 It comes days after another report detailed rapid recovery in fever and respiratory...

http://mfame.guru/gilead-allege-inappropriate-characterizations-of-its-covid19-drug-trial-data/

Join Our Newsletter
Enter your email to receive a weekly round-up of shipping news.
icon
By subscribing, you agree with our privacy policy and our terms of service.